Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)

Recruiting now · Not applicable

Conditions studied: Metastatic Breast Cancer

In brief

A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.

Key facts

Study ID

NCT06459791

Run by

Institut Curie

People needed

110

Starts

2024-12-06

Expected to finish

2028-09-30

Last updated by the study team

2026-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient over 18 years of age
• Advanced breast cancer
• Triple-negative phenotype (HR-/HER2-) or HR+/HER2- after hormone resistance (progression after treatment with hormone therapy + CDK4/6 inhibitor)
• Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy
• Performans Status 0-1

You may not qualify if…

• More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy/CDK4/6 inhibitor)
• Progressive brain metastases
• Leptomeningeal metastasis

Where it is running

• Institut Curie — Paris, France (enrolling)
• Institut Curie — Saint-Cloud, France (enrolling)
• Hôpital Saint-Louis - AP-HP Senopole — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.